Pharmacokinetics of Miltefosine in Children & Adults

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. The results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance.

Clinical Trial Description

An open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. The participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/Kg of weight for 28 days.

Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively. Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment.

A population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of Leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. The relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling. ;

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01462500
Study type	Interventional
Source	Centro Internacional de Entrenamiento e Investigaciones Médicas
Contact
Status	Completed
Phase	Phase 4
Start date	October 2011
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01988909` - WR 279,396 for the Treatment of Cutaneous Leishmaniasis	Phase 2
Enrolling by invitation	`NCT00840359` - Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis	Phase 2
Enrolling by invitation	`NCT00737386` - Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank	N/A
Completed	`NCT00233545` - Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia	Phase 2
Completed	`NCT01011309` - A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis	Phase 2
Completed	`NCT01301924` - Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis	Phase 2/Phase 3
Not yet recruiting	`NCT02281669` - Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients	N/A
Completed	`NCT01464242` - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01790659` - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama	Phase 3
Completed	`NCT01050907` - Miltefosine to Treat Mucocutaneous Leishmaniasis	Phase 2
Completed	`NCT04340128` - Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)	Phase 3
Terminated	`NCT00317629` - Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Phase 3
Completed	`NCT00351520` - Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica	Phase 3
Completed	`NCT01381055` - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01050777` - Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis	Phase 0
Completed	`NCT01380314` - Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis	Phase 2
Terminated	`NCT01380301` - Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony	Phase 2
Completed	`NCT00703924` - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World	Phase 2
Completed	`NCT00344084` - Surveillance for Leishmaniasis Skin Lesions in Mali
Completed	`NCT03023111` - Miltefosine and GM-CSF in Cutaneous Leishmaniasis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pharmacokinetics of Miltefosine in Children and Adults — PK

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms